Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of Hdac3 as a Strategy for Developing Novel Diabetes Therapeutics

1 Apr 2014

Abstract excerpt

Modulation of histone deacetylase (HDAC) activity has been implicated as a potential therapeutic strategy for multiple diseases. Recent studies have put a greater spotlight on metabolic diseases, in particular Type 1 and Type 2 diabetes, as potential indications for which HDAC inhibition could be beneficial. Evidence suggests that inhibition of HDAC3 protects β-cells from cytokine-induced apoptosis, an important...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research
Share to Pancreatic function and diabetes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24811789
DOI: 10.2217/epi.14.11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of Hdac3 as a Strategy for Developing Novel Diabetes TherapeuticsPMID 24811789Read ↗

Histone deacetylases and inhibitors in diabetes mellitus and its complicationsSemantic proximity Read ↗

Exploring histone deacetylases in type 2 diabetes mellitus: pathophysiological insights and therapeutic avenuesSemantic proximity Read ↗

Histone deacetylases and their inhibitors: molecular mechanisms and therapeutic implications in diabetes mellitusSemantic proximity Read ↗

Augmentation of histone deacetylase 3 (HDAC3) epigenetic signature at the interface of proinflammation and insulin resistance in patients with type 2 diabetesSemantic proximity Read ↗

The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes MellitusSemantic proximity Read ↗

Progress toward molecular therapy for diabetes mellitus: A focus on targeting inflammatory factorsSemantic proximity Read ↗

HDAC11, an emerging therapeutic target for metabolic disordersSemantic proximity Read ↗

Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.Semantic proximity Read ↗

Pharmacological HDAC inhibition impairs pancreatic β-cell function through an epigenome-wide reprogrammingSemantic proximity Read ↗

The role of HDAC3 in inflammation: mechanisms and therapeutic implicationsSemantic proximity Read ↗

HDAC7 is overexpressed in human diabetic islets and impairs insulin secretion in rat islets and clonal beta cellsSemantic proximity Read ↗

Histone Deacetylase Inhibitors and Diabetic Kidney DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.